pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda medwatch·19h ago·3 min read
save

Early Alert: B. Braun Medical Inc. Removes Streamline Bloodline Set for Dialog+

The dialyzer connector may not be attached appropriately, resulting in leaking and potential blood loss.

Nov 2, 2026·read at fda medwatch ↗RegulatoryNeutral

CDRH is issuing this Early Alert to notify the public of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available.Affected ProductThe FDA is aware that B. Braun Medical Inc.

has issued a letter to affected customers recommending certain Hemodialysis Bloodlines be removed from where they are used or sold. Product Description: Streamline Bloodline Set for Dialog+Model: SL-2010M2096UDI-DI: 04046964367786; 04046964367779Impacted Lots: A2600099, A2600128, A2600136What to DoEnsure all users are informed of the recall. Identify and quarantine all affected devices.On October 20, 2026, B.

Braun Medical Inc. sent all affected customers a letter recommending the following actions:Ensure all users in your organization and other concerned persons are informed about this recall. If you are a distributor, please forward this notice to your consignees.

Determine inventory of the affected items, cease use and quarantine product subject to recall. Return affected product to the manufacturer.Check this web page for updates. The FDA is currently reviewing information about this potentially high-risk device issue and will keep the public informed as significant new information becomes available.Reason for AlertB.

Braun Medical Inc. stated that the required solvent application step during assembly was not performed, resulting in inadequate bonding of the dialyzer connector. As a result, the bloodline connector may detach or leak during priming or dialysis treatment, potentially leading to blood loss, clotting and occlusion of the extracorporeal circuit, and/or air ingress into the blood circuit.

If the arterial tubing detaches, partially separates, or leaks during dialysis treatment, blood may be lost from the extracorporeal circuit, and the treatment may need to be interrupted while the bloodline is replaced. In some cases, blood loss may also occur due to clotting and occlusion of the bloodline, requiring replacement of the extracorporeal circuit. Hemodialysis patients are medically fragile, and extracorporeal blood loss may require clinical assessment, corrective treatment, professional medical intervention, or hospitalization.

In severe cases, significant blood loss could be life-threatening.Inadequate bonding may also result in leakage or partial separation of the arterial tubing connection, permitting air entry into the blood circuit. Air entering the blood circuit is expected to be detected by the dialysis machine's air detection system and managed by healthcare personnel; however, treatment interruption, bloodline replacement, additional patient assessment and monitoring, and medical intervention may be required. In extremely rare circumstances, air that passes the dialysis machine air detection system could result in air embolism and death.As of October 10, 2026, B.

Braun Medical Inc. has reported no serious injuries or deaths associated with this issue.Device UseThe Streamline Bloodline Set for Dialog+ Hemodialysis System is a blood tubing set indicated for hemodialysis.Contact InformationCustomers in the U.S. with adverse reactions, quality problems, or questions about this recall should contact B.

Braun Medical Inc. at recalls@bbraunusa.com or (610) 849-1197.Unique Device Identifier (UDI)The unique device identifier (UDI) helps identify individual medical devices sold in the United States from distribution to use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified more quickly, and as a result, problems potentially resolved more quickly.How do I recognize a UDI on a label?AccessGUDID database – Identify Your Medical DeviceBenefits of a UDI SystemHow do I report a problem?Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

source

Reporting by fda medwatch.

read at fda medwatch ↗
568 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
B. Braun Medical Inc5UNIQUE2LEADINGUltragenyx Pharmaceutical Inc.
topics
Hematology10Recall4Rare Disease

related stories

  • 6d agoEarly Alert: B. Braun Removes Streamline Bloodline Set for Dialog+fda medwatch
  • 8h agoVistagen cuts workforce for second time in 2026BioSpace
  • Oct 19Should amylin have been obesity therapeutics’ primary target from the start?BioSpace
  • Sep 7BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancerFierce Biotech
  • Jul 24Amgen deploys patients to defend troubled Tavneos in FDA hearing requestBioSpace